Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. - Test2 - elhamkhani - TriplyDB

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

http://www.wikidata.org/entity/Q35121793

about

Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease Stimulation of incretin secreting cells Hunger and Satiety Mechanisms and Their Potential Exploitation in the Regulation of Food Intake Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1 Intervention Trials with the Mediterranean Diet in Cardiovascular Prevention: Understanding Potential Mechanisms through Metabolomic Profiling The Metabolic Responses to L-Glutamine of Livers from Rats with Diabetes Types 1 and 2 Does oral glutamine improve insulin sensitivity in adolescents with type 1 diabetes?Differential effects of L-tryptophan and L-leucine administration on brain resting state functional networks and plasma hormone levels.Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats.The use of exenatide in severely burned pediatric patients.Side effects of long-term glutamine supplementation.Effects of L-glutamine supplementation on maternal and fetal hemodynamics in gestating ewes exposed to alcohol Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor.Gut chemosensing mechanisms.Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.Enteral supplementation with glutamine, fiber, and oligosaccharide modulates incretin and glucagon-like peptide-2 secretion L-glutamine and whole protein restore first-phase insulin response and increase glucagon-like peptide-1 in type 2 diabetes patients.Effects of Intraduodenal Infusions of L-phenylalanine and L-glutamine on Antropyloroduodenal Motility and Plasma Cholecystokinin in Healthy Men Metabolite profiling identifies pathways associated with metabolic risk in humans (-)-Epigallocatechin-3-gallate induces secretion of anorexigenic gut hormones Nutritional regulation of insulin secretion: implications for diabetes.Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance.Plasma Free Amino Acid Responses to Intraduodenal Whey Protein, and Relationships with Insulin, Glucagon-Like Peptide-1 and Energy Intake in Lean Healthy Men.Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.Effect of the ingestion of the palm oil and glutamine in serum levels of GLP-1, PYY and glycemia in diabetes mellitus type 2 patients submitted to metabolic surgery The effect of encapsulated glutamine on gut peptide secretion in human volunteers.Circulating glucagon-like peptide-1 increases in response to short-term overfeeding in men.Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes Metabolomics in diabetic complications.The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: a preclinical assessment.Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvención con DIeta MEDiterránea (PREDIMED) Trial.Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: A (1)H NMR-based metabolomics investigation.Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport.Molecular mechanisms underlying nutrient-stimulated incretin secretion.Molecular mechanisms underlying nutrient detection by incretin-secreting cells.Luminal chemosensing in the duodenal mucosa.The future of incretin-based therapy: novel avenues--novel targets.

P2860

Q26741117-A742A925-2D96-4A1E-8A70-66410B05B573 Q26765259-01344144-737F-46E5-8AD7-5A2C566C83BD Q26772113-557B057D-180B-42BD-A044-2BBF956FA3DA Q26781127-011AD469-B991-420D-B274-87648B27A297 Q28274033-261923E8-EE41-4A33-ADBF-109DF364E182 Q28553380-B59DD38E-21C7-44C1-B710-DBAC1AA0AAB4 Q30275067-96B92369-F150-47B8-B2E5-A35498E16FD2 Q31137814-1C550593-7AB8-4D42-A343-ABD170EC6BC5 Q34085334-33EDE271-224D-491F-A5E1-CC495ED9DCC4 Q34153353-958AD250-6F46-4C6A-9EA0-EA00919996F7 Q34300553-B82B6470-C40C-4329-8038-50A637BF3497 Q34361253-4659C676-2324-49C0-AB85-68BC1718D00A Q34550022-DF730A03-FBD9-46BC-8745-71C179C48A72 Q34991604-D8631940-848F-4C5E-A103-A612194C2605 Q35183915-226B581E-2A4A-43A9-853C-70E1D023FC6F Q35429613-CBD0919F-66AD-43B6-9A39-34CB6AFAC497 Q35571826-BA698582-FA38-4CFB-9AF8-DBC6F0122F7C Q35585816-B2EF52C3-C10A-451E-838C-4E405C6A5FC9 Q35834493-C684ED28-6619-4443-8669-ACF86E9A3FA5 Q36037142-983D89F4-DD22-4AD6-A021-18CA81B0F63F Q36049132-50F159DB-793E-4B7C-8080-14A039AE1979 Q36071152-8A34A9C4-CC15-46B6-A94E-19EE68636926 Q36476147-C33E5BF0-8D80-40B3-976C-01FF864B0D95 Q36507384-38B76877-638F-40BF-B3C5-7DC97E9B8394 Q36528937-7514073A-3022-44A1-9CB7-9C7B3E2341E4 Q36550768-86FC7F38-EB74-473C-8347-E5A0B217F2B3 Q36678609-118FF9C9-8D91-4DEF-B323-879FAE331777 Q36766657-1B09681C-2395-49E9-BB61-766B88FB6D6D Q37022735-393D801E-76A0-4784-BF06-F0B2C2849DC5 Q37041169-9706B02B-FF15-457B-9E12-9FC5433A1377 Q37189170-7374A891-ABE4-45CD-899F-46EF8829CF8D Q37240144-4A4B0616-43DA-4DC5-AA56-02B877EAFD29 Q37364462-C8CC5385-48AC-4AF6-A802-FF307713F8D7 Q37382378-6D962169-6713-40AC-BB69-170B9F2A29FA Q37390264-7D9E1CF9-6F32-4A9A-9330-E763933293D4 Q37662980-68ACB8F5-B164-4E32-ACCC-6470EAC68164 Q37667168-114E86FC-CAF9-4F28-83B8-99E4F3E8D0F3 Q37702790-5D0122C0-8C70-4332-A954-9E0D75C6F77A Q37762287-AA866909-10F0-441D-819F-4123FBF39D45 Q37913528-C48A5DA3-1CA3-4874-98DD-4953FDA67DD9

P2860

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

http://www.wikidata.org/entity/Q35121793

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@ast

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@en

type

label

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@ast

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@en

prefLabel

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@ast

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@en

P1433

Q35121793-03CCB25D-D58B-46B6-BAF1-EB158222CBC9

P1476

Q35121793-722B5A48-A703-43E2-8E92-916BEB2DB390

P2093

Q35121793-434DE904-A7AF-4A08-A1FD-EF1001CFADD8

Q35121793-E1312AFE-95A2-4E85-B8C5-78966AEF079A

Q35121793-E71D694B-9D64-4B26-9DFE-591A191ECBB4

Q35121793-F5FBCC13-7DE5-48D4-B9B3-07125DB64B19

P2860

Q35121793-03D0A477-B7C3-4CEF-B8E7-B2C84867CA94

Q35121793-086D19FB-1D22-4E14-86B9-AE65BE11D909

Q35121793-08B01724-6320-4371-9DD2-C725FE4B1074

Q35121793-0B0D345A-5A30-4A2E-B423-43DCA60560F2

Q35121793-166031BC-A301-4AA1-BB1A-6693B2232AB9

Q35121793-256846D4-861E-4606-B170-566FF0550681

Q35121793-2A74E6E3-713B-4DFB-AF02-3BDDC5F8D7AE

Q35121793-2F997C3D-029B-4C34-BACF-3FAD0E68316E

Q35121793-3AF5A2ED-0164-4B83-B3F0-ADF6EF5992CA

Q35121793-3BE42E4E-818F-479A-8BAE-AC0B88092E73

P304

Q35121793-9F39D49D-2DEC-4D50-B78D-7FB6B20A6B7A

P31

Q35121793-8800DF04-95D7-406F-BC9B-EC0F77DDA324

P356

Q35121793-1AFAAB2A-C058-48D0-BDB7-294F84642DB7

P407

Q35121793-9BB664B6-CDD6-4B88-800C-57F817AB1EC6

P433

Q35121793-E6B5F421-1835-428E-AC4E-F5160DE2D519

P478

Q35121793-E1308E91-EB6F-4920-BDA4-661D142505BD

P50

Q35121793-18FBE83C-E7A1-4E27-BB75-BD6893D071C5

Q35121793-51A1E644-0B3E-4F40-95CE-F2B43FFF6BF1

Q35121793-75C590B2-485C-4D68-9E42-30402995A945

Q35121793-78019D56-E28C-4EA8-B37F-E6979C149CE2

Q35121793-7965463A-F934-4EF6-98D3-FBC2F6455AD6

P577

Q35121793-142FBE71-BEE1-43A3-A8AD-08B3221D4959

P5875

Q35121793-307DCED4-447A-49DA-A645-AF18EA43822F

P698

Q35121793-CB25A03B-B188-442A-AF58-D642A8F2CFD8

P921

Q35121793-1F3A9694-2786-4ABB-B018-20CE35DA446C

Q35121793-C2754E08-560B-4EFE-908B-4732566487F1

P932

Q35121793-DF812538-CAFE-4AA1-8D61-1E117ECEB565

P356

AJCN.2008.26362

P1433

The American Journal of Clinical Nutrition

P1476

Oral glutamine increases circu ...... and type 2 diabetic subjects.

@en

P2093

Anthea Blackwood

http://www.w3.org/2001/XMLSchema#string

Elana Henning

http://www.w3.org/2001/XMLSchema#string

Jerry R Greenfield

http://www.w3.org/2001/XMLSchema#string

Julia M Keogh

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

Inhibition of food intake in obese subjects by peptide YY3-36

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

Intestinal mucosal amino acid catabolism

Gut hormone PYY(3-36) physiologically inhibits food intake.

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Glutamine and the bowel.

Incretins, insulin secretion and Type 2 diabetes mellitus.

Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide.

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

P304

106-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3945/AJCN.2008.26362

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

Fiona M Gribble

Abdella M Habib

P577

2008-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23571522

http://www.w3.org/2001/XMLSchema#string

P698

19056578

http://www.w3.org/2001/XMLSchema#string

P921

P932

4340573

http://www.w3.org/2001/XMLSchema#string